Pure Global
NCT06137300

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke：a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial
Yi Yang·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
Urinary kallidinogenase for injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yi Yang
Funder
The First Hospital of Jilin University
Location
Changchun, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 31, 2027
Enrollment
986 participants
Primary outcome

Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 at 90 days

Summary

The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase
 treatment in patients with large artery atherosclerotic acute ischemic stroke.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06137300
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06137300 through Pure Global AI's free database. This phase not specified trial is sponsored by Yi Yang and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 986 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.